Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
THE BEST BLACK FRIDAY DEAL YET (Ad)
On outskirts of Doha, laborers watch World Cup they built
Whole Foods decision to pull lobster divides enviros, pols
THE BEST BLACK FRIDAY DEAL YET (Ad)
Railway workers in Austria to strike Monday in pay standoff
Airbnb has a plan to fix cleaning fees
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
THE BEST BLACK FRIDAY DEAL YET (Ad)
On outskirts of Doha, laborers watch World Cup they built
Whole Foods decision to pull lobster divides enviros, pols
THE BEST BLACK FRIDAY DEAL YET (Ad)
Railway workers in Austria to strike Monday in pay standoff
Airbnb has a plan to fix cleaning fees
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
THE BEST BLACK FRIDAY DEAL YET (Ad)
On outskirts of Doha, laborers watch World Cup they built
Whole Foods decision to pull lobster divides enviros, pols
THE BEST BLACK FRIDAY DEAL YET (Ad)
Railway workers in Austria to strike Monday in pay standoff
Airbnb has a plan to fix cleaning fees
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
THE BEST BLACK FRIDAY DEAL YET (Ad)
On outskirts of Doha, laborers watch World Cup they built
Whole Foods decision to pull lobster divides enviros, pols
THE BEST BLACK FRIDAY DEAL YET (Ad)
Railway workers in Austria to strike Monday in pay standoff
Airbnb has a plan to fix cleaning fees
NASDAQ:CTXR

Citius Pharmaceuticals - CTXR Stock Forecast, Price & News

$1.19
+0.03 (+2.59%)
(As of 11/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.13
$1.19
50-Day Range
$1.02
$1.28
52-Week Range
$0.83
$2.01
Volume
155,342 shs
Average Volume
465,936 shs
Market Capitalization
$173.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Citius Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
320.2% Upside
$5.00 Price Target
Short Interest
Bearish
7.36% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.85mentions of Citius Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.20) to $0.19 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.81 out of 5 stars

Medical Sector

858th out of 1,044 stocks

Pharmaceutical Preparations Industry

416th out of 510 stocks

CTXR stock logo

About Citius Pharmaceuticals (NASDAQ:CTXR) Stock

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Receive CTXR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Citius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CTXR Stock News Headlines

Citius Pharmaceuticals, Inc. to Present at the H....
See More Headlines
Receive CTXR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Citius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CTXR Company Calendar

Last Earnings
8/12/2021
Today
11/27/2022
Next Earnings (Estimated)
12/21/2022
Fiscal Year End
9/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CTXR
Fax
N/A
Employees
15
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+320.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-23,050,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.91 per share

Miscellaneous

Free Float
124,503,000
Market Cap
$173.89 million
Optionable
Not Optionable
Beta
1.16

Key Executives

  • Mr. Leonard L. Mazur (Age 77)
    Co-Founder, CEO, Chairman & Sec.
    Comp: $592.92k
  • Mr. Myron Z. Holubiak (Age 75)
    Co-Founder & Exec. Vice Chairman
    Comp: $1.48M
  • Mr. Jaime Bartushak (Age 54)
    Chief Bus. Officer, CFO & Chief Accounting Officer
    Comp: $500.93k
  • Dr. Myron S. Czuczman M.D. (Age 62)
    Exec. VP & Chief Medical Officer
    Comp: $549.67k
  • Mr. Gary F. Talarico (Age 67)
    Exec. VP of Operations
  • Ms. Ilanit Allen
    VP of Investor Relations & Corp. Communications
  • Dr. Alan Lader Ph.D.
    Sr. VP & Head of Clinical Operations and Quality Assurance
  • Mr. Dhananjay G. Wadekar (Age 68)
    Sr. VP of Bus. Strategy
  • Mr. Kelly Creighton Ph.D.
    Exec. VP of Chemistry, Manufacturing & Controls













CTXR Stock - Frequently Asked Questions

Should I buy or sell Citius Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Citius Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CTXR shares.
View CTXR analyst ratings
or view top-rated stocks.

What is Citius Pharmaceuticals' stock price forecast for 2023?

2 analysts have issued 1 year target prices for Citius Pharmaceuticals' stock. Their CTXR share price forecasts range from $4.00 to $6.00. On average, they predict the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 320.2% from the stock's current price.
View analysts price targets for CTXR
or view top-rated stocks among Wall Street analysts.

How have CTXR shares performed in 2022?

Citius Pharmaceuticals' stock was trading at $1.54 at the beginning of 2022. Since then, CTXR stock has decreased by 22.7% and is now trading at $1.19.
View the best growth stocks for 2022 here
.

When is Citius Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, December 21st 2022.
View our CTXR earnings forecast
.

How were Citius Pharmaceuticals' earnings last quarter?

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) posted its quarterly earnings data on Thursday, August, 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.05).

When did Citius Pharmaceuticals' stock split?

Citius Pharmaceuticals shares reverse split before market open on Friday, June 9th 2017. The 1-15 reverse split was announced on Thursday, June 8th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 8th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Citius Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Citius Pharmaceuticals investors own include Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Novan (NOVN), ADMA Biologics (ADMA), SCYNEXIS (SCYX), Aeterna Zentaris (AEZS), CBL & Associates Properties (CBL), KushCo (KSHB) and Gran Tierra Energy (GTE).

What is Citius Pharmaceuticals' stock symbol?

Citius Pharmaceuticals trades on the NASDAQ under the ticker symbol "CTXR."

Who are Citius Pharmaceuticals' major shareholders?

Citius Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.98%), BlackRock Inc. (1.60%), Renaissance Technologies LLC (0.27%), Ergoteles LLC (0.26%), SG Americas Securities LLC (0.06%) and Kestra Advisory Services LLC (0.06%).
View institutional ownership trends
.

How do I buy shares of Citius Pharmaceuticals?

Shares of CTXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Citius Pharmaceuticals' stock price today?

One share of CTXR stock can currently be purchased for approximately $1.19.

How much money does Citius Pharmaceuticals make?

Citius Pharmaceuticals (NASDAQ:CTXR) has a market capitalization of $173.89 million. The company earns $-23,050,000.00 in net income (profit) each year or ($0.20) on an earnings per share basis.

How can I contact Citius Pharmaceuticals?

Citius Pharmaceuticals' mailing address is 11 Commerce Drive First Floor, Cranford NJ, 07016. The official website for the company is www.citiuspharma.com. The company can be reached via phone at (908) 967-6677 or via email at ir@citiuspharma.com.

This page (NASDAQ:CTXR) was last updated on 11/27/2022 by MarketBeat.com Staff